Sarepta Therapeutics, Inc. conducted its fourth quarter 2025 earnings call on February 25, 2026. The company released its financial results earlier that day, with details available on its website. Executives including CEO Douglas Ingram participated in the discussion.
Sarepta Therapeutics, Inc. (SRPT) hosted its Q4 2025 earnings results call at 4:30 PM EST on February 25, 2026. The event was recorded, as announced by the operator at the start.
Tamara Thornton, Director of Finance, Treasury & Investor Relations, opened the call by thanking participants and noting that the financial results for the fourth quarter of 2025 had been released earlier in the afternoon. She directed listeners to the press release and slides in the Investors section of the company's website at sarepta.com. Thornton also mentioned that the 10-K filing would be submitted to the Securities and Exchange Commission the following Monday.
Key company participants included Douglas Ingram, CEO & Director; Patrick Moss, Executive VP & Chief Commercial Officer; Louise Rodino-Klapac, President of Research & Development and Technical Operations; and Ryan Wong, Executive VP & CFO. The call featured questions from analysts such as Anupam Rama from JPMorgan Chase & Co., Brian Abrahams from RBC Capital Markets, and others from firms including Barclays, Jefferies, Leerink Partners, Goldman Sachs, BofA Securities, H.C. Wainwright, Morgan Stanley, Piper Sandler, Oppenheimer, TD Cowen, Bernstein, Needham, William Blair, and Wolfe Research.
Following introductory remarks, the session was set to open for questions from the analysts. The call provided an opportunity for Sarepta to discuss its performance in the gene therapy and rare disease sectors, though specific financial details were outlined in the accompanying press release.